SB
SRRA

Strategic Blueprint’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Strategic Blueprint’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-782
Closed -$15K – 1425
2021
Q2 		$15K Buy
+782
New +$14.2K ﹤0.01% 886

Other funds holding SRRA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Strategic Blueprint's SRRA Position: Q3 2021 in Review

Strategic Blueprint sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2021, closing a stake of 782 shares — an estimated $15K sold.

Strategic Blueprint first reported a position in SRRA in Q2 2021 and held it in 1 quarter. The position peaked at $15K in Q2 2021. 37 funds tracked by Wall St. Rank hold SRRA as of Q3 2021.

  • Strategic Blueprint reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Strategic Blueprint sold 782 Sierra Oncology, Inc. Common Stock shares in Q3 2021, an estimated $15K.
  • Strategic Blueprint first reported a position in Sierra Oncology, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Strategic Blueprint's Sierra Oncology, Inc. Common Stock position peaked at $15K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2021.

Based on Strategic Blueprint's 13F filing for Q3 2021, filed 12 Nov 2021.